My Application Form Status

Check the status of your application form with Angel Broking.
Jindal Drilling & Industries standalone net profit declines 3.66% in the June 2016 quarter

Jindal Drilling & Industries standalone net profit declines 3.66% in the June 2016 quarter

Sep 14,2016

Net profit of Jindal Drilling & Industries declined 3.66% to Rs 9.48 crore in the quarter ended June 2016 as against Rs 9.84 crore during the previous quarter ended June 2015. Sales rose 11.24% to Rs 92.66 crore in the quarter ended June 2016 as against Rs 83.30 crore during the previous quarter ended June 2015.

ParticularsQuarter Ended
n++Jun. 2016Jun. 2015% Var.
Sales92.6683.3011
OPM %9.8912.74-
PBDT14.5518.68-22
PBT12.0915.01-19
NP9.489.84-4

Powered by Capital Market - Live News

Kaya allots equity shares
Dec 14,2016

Kaya announced that 3674 equity shares of face value of Rs. 10/- each have been issued and allotted under the Kaya Limited Employees Stock Option Scheme 2014 (n++Schemen++) by the authorized Nomination and Remuneration Committee of the Board of Directors through a Circular Resolution passed on 14 December 2016.

Consequently, the issued, subscribed and paid up capital of the Company stands increased to 12997571 equity shares of face value of Rs. 10 each.

Powered by Capital Market - Live News

Board of Sujana Metal Products approves change in directorate
Dec 14,2016

Sujana Metal Products announced that the Board of Directors of the Company at its meeting held on 14 December 2016, has approved the following:

- Appointed Ram Kumar on the Board of the Company as the Nominee of Punjab National Bank in place of Vimlesh Kumar.

Powered by Capital Market - Live News

Swan Energy signs MoU with Petronasr and Alpha Energy
Dec 14,2016

Swan Energy announced that the Company has signed a MOU with Petronasr and Alpha Energy for the development of SEPHIED BAGHUN gas field, which has approximately 20 tcf reserves, in the Islamic Republic of Iran by constructing necessary on-shore surface facilities and offshore gas liquefaction facilities (OLNG). The project cost is estimated to be around 615 million USD.

Powered by Capital Market - Live News

Advanced Enzyme Technologies appoints director
Dec 14,2016

Advanced Enzyme Technologies announced that the Board of Directors have approved by Circular Resolution dated on 14 December 2016 appointment of Pramod Kasat as an Independent Non-Executive Director as an additional director on the Board of Directors of the Company, who shall hold office upto the date of the next General Meeting of the Company.

Powered by Capital Market - Live News

Sunteck Realty corrects on profit booking
Dec 14,2016

Meanwhile, the BSE Sensex was down 82.06 points, or 0.31%, to 26,615.76.

On the BSE, so far 2.25 lakh shares were traded in the counter, compared with average daily volumes of 35,770 shares in the past one quarter. The stock had hit a high of Rs 230.40 and a low of Rs 219 so far during the day.

The stock hit a 52-week high of Rs 300 on 30 October 2016. The stock hit a 52-week low of Rs 173 on 12 February 2016. The stock had outperformed the market over the past 30 days till 13 December 2016, rising 6.18% compared with the 0.45% decline in the Sensex. The scrip had, however, underperformed the market in past one quarter, falling 10.53% as against Sensexs 5.90% decline.

The small-cap company has equity capital of Rs 12.59 crore. Face value per share is Rs 2.

Shares of Sunteck Realty rose 18.41% in four trading sessions to settle at Rs 227.65 yesterday, 13 December 2016, from its close of Rs 192.25 on 7 December 2016.

The stock surged 9.55% to Rs 227.65 yesterday, 13 December 2016, after the company reported robust Q2 earnings after market hours on Monday, 12 December 2016. Sunteck Realtys net profit surged 526.40% to Rs 97.28 crore on 582.32% rise in total income from operations to Rs 206.06 crore in Q2 September 2016 over Q2 September 2015.

Sunteck Realty (SRL) is a Mumbai‐based real estate development company, catering to the premium ultra‐luxury and luxury residential segment.

Powered by Capital Market - Live News

Royal Orchid Hotels advances after adding two more hotels
Dec 14,2016

The announcement was made after market hours yesterday, 13 December 2016.

Meanwhile, the BSE Sensex was down 48.55 points, or 0.18%, to 26,649.27.

On the BSE, 9,542 shares were traded in the counter so far as against average daily volume of 16,342 shares in the past one quarter. The stock had hit a high of Rs 77.65 and a low of Rs 74.60 so far during the day. The stock had hit a 52-week high of Rs 115.10 on 11 January 2016. The stock had hit a 52-week low of Rs 56.60 on 17 February 2016.

The stock had outperformed the market over the past 30 days till 13 December 2016, rising 1.52% compared with 0.45% decline in the Sensex. The scrip had also outperformed the market in past one quarter, gaining 19.3% as against Sensexs 5.84% decline.

The small-cap company has equity capital of Rs 27.23 crore. Face value per share is Rs 10.

Royal Orchid Hotels announced the opening of two hotels under its brand Regenta Inn in Vadodara and Kolkata, which are slated to open on 15 December 2016, expanding count to 40 hotels by the end of 2016.

The brand Regenta Hotels is an upscale arm of the Royal Orchid Hotels group. It is categorized into Regenta, Regenta Central, Regenta Resorts and Regenta Inn.

Royal Orchid Hotels net profit rose 33.7% to Rs 2.74 crore on 8.7% decline in net sales to Rs 19.19 crore in Q2 September 2016 over Q2 September 2015.

Royal Orchid Hotels operates business and leisure hotels in popular destinations.

Powered by Capital Market - Live News

WPI inflation eases to 3.2% in November 2016
Dec 14,2016

The Wholesale Price Index (WPI)-based inflation eased for the third straight month to 3.2% in November 2016 from 3.4% in October 2016. The decline in WPI inflation was entirely driven by a dip in inflation for primary articles, while fuel and power and manufactured products group inflation continued to rise in November 2016. Further, the unfavourable base effect restricted sharp decline in inflation in November 2016.

Inflation of primary articles dipped to 1.2% in November 2016 from 3.3% in October 2016. The inflation for manufactured products rose to 3.2% in November 2016. Further, the inflation for fuel items accelerated further to 7.1% in November 2016 from 6.2% in October 2016.

As per major commodity group-wise, inflation eased for fruits, vegetables, egg, fish, spices, fibres, oilseeds, flowers, edible oils, oilcakes, tea, beverages and tobacco products, wood and products, non-metallic mineral products and automotives in November 2016. On the other hand, inflation of foodgrains, coffee, sugarcane, iron ore, crude petroleum, mineral oils, grain mill products, sugar, textiles, paper products, leather products, rubber products, chemical products, and basic metals rose in November 2016.

Inflation of food items (food articles and food products) eased to 4.4% in November 2016 from 6.3% in October 2016. Meanwhile, inflation of non-food items (all commodities excluding food items) moved up to 2.6% in November 2016 from 2.1% in October 2016.

Core inflation (manufactured products excluding foods products) rose to 24-months high of 1.5% in November 2016 from 1.1% in October 2016.

The contribution of primary articles to the overall inflation, at 3.15%, was 36 basis points (bps) in November 2016 compared with 96 bps in October 2016. The contribution of manufactured products was 179 bps compared with 151 bps, while that of fuel product group was 106 bps against 92 bps in October 2016.

The contribution of food items (food articles and food products) to inflation fell to 140 bps in 3.39% in November 2016 compared with 197 bps to 3.39% in October 2016. Meanwhile, the contribution of non-food items (all commodities excluding food items) was 179 bps in November 2016 compared with 144 bps in October 2016.

As per the revised data, the inflation figure for September 2016 was revised up to 3.8% compared with 3.6% reported provisionally.

Powered by Capital Market - Live News

Lupin marches ahead after receiving final USFDA approval for generic ointment
Dec 14,2016

The announcement was made during market hours today, 14 December 2016.

Meanwhile, the BSE Sensex was down 26.61 points, or 0.1%, to 26,671.21.

On the BSE, 20,653 shares were traded on the counter so far as against the average daily volumes of 96,866 shares in the past one quarter. The stock had hit a high of Rs 1,509 and a low of Rs 1,482.40 so far during the day. The stock had hit a 52-week high of Rs 1,911.55 on 9 February 2016. The stock had hit a 52-week low of Rs 1,294.05 on 29 March 2016.

The stock had outperformed the market over the past 30 days till 13 December 2016, gaining 2.19% compared with 0.45% decline in the Sensex. The scrip had also outperformed the market in past one quarter, falling 2.67% as against Sensexs 5.84% decline.

The large-cap company has equity capital of Rs 90.27 crore. Face value per share is Rs 2.

Lupin announced that it has received final approval for its Desoximetasone Ointment USP, 0.05% from the United States Food & Drug Administration (USFDA) to market a generic version of Taro Pharms Norths Topicort Ointment, 0.05%. The product filing is from Lupins Pithampur, Indore manufacturing facility.

Lupins Desoximetasone Ointment USP, 0.05% is the AB rated generic equivalent of Taro Pharms Norths Topicort Ointment, 0.05%. It is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Topicort Ointment had annual US sales of $12.1 million as per the IMS MAT September 2016 data.

Earlier this month, Lupin had received final approval for its Desoximetasone Ointment USP, 0.25% from US FDA to market a generic version of Taro Pharmaceuticals, Inc.s Topicort Ointment, 0.25% having annual US sales of $14.4 million as per the IMS MAT September 2016 data.

Lupins consolidated net profit jumped 57.8% to Rs 662.19 crore on 31.9% rise in net sales to Rs 4211.18 crore in Q2 September 2016 over Q2 September 2015.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Powered by Capital Market - Live News

Lupin marches ahead after receiving final USFDA approval for generic ointment
Dec 14,2016

The announcement was made during market hours today, 14 December 2016.

Meanwhile, the BSE Sensex was down 26.61 points, or 0.1%, to 26,671.21.

On the BSE, 20,653 shares were traded on the counter so far as against the average daily volumes of 96,866 shares in the past one quarter. The stock had hit a high of Rs 1,509 and a low of Rs 1,482.40 so far during the day. The stock had hit a 52-week high of Rs 1,911.55 on 9 February 2016. The stock had hit a 52-week low of Rs 1,294.05 on 29 March 2016.

The stock had outperformed the market over the past 30 days till 13 December 2016, gaining 2.19% compared with 0.45% decline in the Sensex. The scrip had also outperformed the market in past one quarter, falling 2.67% as against Sensexs 5.84% decline.

The large-cap company has equity capital of Rs 90.27 crore. Face value per share is Rs 2.

Lupin announced that it has received final approval for its Desoximetasone Ointment USP, 0.05% from the United States Food & Drug Administration (USFDA) to market a generic version of Taro Pharms Norths Topicort Ointment, 0.05%. The product filing is from Lupins Pithampur, Indore manufacturing facility.

Lupins Desoximetasone Ointment USP, 0.05% is the AB rated generic equivalent of Taro Pharms Norths Topicort Ointment, 0.05%. It is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Topicort Ointment had annual US sales of $12.1 million as per the IMS MAT September 2016 data.

Earlier this month, Lupin had received final approval for its Desoximetasone Ointment USP, 0.25% from US FDA to market a generic version of Taro Pharmaceuticals, Inc.s Topicort Ointment, 0.25% having annual US sales of $14.4 million as per the IMS MAT September 2016 data.

Lupins consolidated net profit jumped 57.8% to Rs 662.19 crore on 31.9% rise in net sales to Rs 4211.18 crore in Q2 September 2016 over Q2 September 2015.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Powered by Capital Market - Live News

Geometric provides update on scheme of arrangement and amalgamation
Dec 14,2016

Geometric announced that it has received the approval of the Honble Bombay High Court on 02 December 2016 for the proposed scheme of arrangement and amalgamation among Geometric, HCL Technologies, being listed companies, 3D PLM Software Solutions, an unlisted Company, and their respective shareholders and creditors.

The completion of the scheme is subject to various conditions precedent including the sanction of the Honble Delhi High Court.

Powered by Capital Market - Live News

Lupin gets final approval to market generic Topicortn++ Ointment
Dec 14,2016

Lupin announced that it has received final approval for its Desoximetasone Ointment USP, 0.05% mg from the United States Food & Drug Administration to market a generic version of Taro Pharms Norths Topicortn++ ointment, 0.05%.

Powered by Capital Market - Live News

Shiva Medicare announces resignation of company secretary
Dec 14,2016

Shiva Medicare announced Karthik Allenkala has resigned from the post of Company Secretary of the Company.

The Board of Directors noted the same in their held board meeting and the same was intimated to the exchange on 06 December 2016 Board Meeting outcome.

Consequent to his resignation as Company Secretary, Karthik Allenkala also ceases to be Compliance Officer of the Company.

Powered by Capital Market - Live News

Shashijit Infraprojects secures contract from existing customer
Dec 14,2016

Shashijit Infraprojects has secured another project from its customer, Sanathan Textiles for construction of new cotton warehouse in Silvassa as part of their expansion programme. The project cost is approx. Rs 1.50 crore. The project is likely to be completed by February 2017.

Powered by Capital Market - Live News

Rishiroop allots preference shares
Dec 14,2016

Rishiroop announced that the Securities Issue Committee of the Board of Directors of the Company has in the meeting held on 14 December 2016 approved allotment of 1080 equity shares of Rs. 10/- each of the Company to holders of Optionally Convertible Preference Shares (OCPS) who exercised their option to convert their OCPS holding to equity shares as per the terms of the Scheme of Amalgamation (Scheme) sanctioned by the Honble High Court of Judicature at Bombay vide its order dated 08 May 2015, and Honble High Court of Gujarat at Ahmedabad vide its order dated 23 June 2015.

Powered by Capital Market - Live News

Arfin India announces resignation of CFO
Dec 14,2016

Arfin India announced that Vijay Lathi has resigned from the Post of Chief Financial Officer of the Company with effect from closure of working hours of 13 December 2016.

Powered by Capital Market - Live News